Golvatinib, also known as E-7050, is an investigational, orally bioavailable small-molecule drug that functions as a potent dual inhibitor of the c-Met (HGF receptor) and VEGFR-2 tyrosine kinases. By blocking these receptors, it aims to suppress tumor growth, survival, migration, and angiogenesis in various cancers.Developed initially by Eisai, this compound was mainly investigated for the treatment of advanced solid tumors, including gastric cancer, hepatocellular carcinoma, and platinum-resistant squamous cell carcinoma of the head and neck. It is grouped under the following drug class(es): Tyrosine Kinase Inhibitors. The directory classifies it as a discontinued API with a synthetic source/manufacturing origin. Other names for this substance include golvatinibum. Its PubChem CID is 16118392.
Golvatinib
| CAS No | 928037-13-2 |
|---|---|
| Molecular Formula | C33H37F2N7O4 |
| Molecular Weight | 633.70 g/mol |
| Synonyms | 1-N'-[2-fluoro-4-[[2-[[4-(4-methylpiperazin-1-yl)piperidine-1-carbonyl]amino]-4-pyridinyl]oxy]phenyl]-1-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Golvatinib, also known as E-7050, is an investigational, orally bioavailable small-molecule drug that functions as a potent dual inhibitor of the c-Met (HGF receptor) and VEGFR-2 tyrosine kinases.
The listed CAS number is 928037-13-2.
The listed molecular formula is C33H37F2N7O4.
The listed molecular weight is 633.70 g/mol.
1-N'-[2-fluoro-4-[[2-[[4-(4-methylpiperazin-1-yl)piperidine-1-carbonyl]amino]-4-pyridinyl]oxy]phenyl]-1-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide.
The source lists golvatinibum.